Field of Science

  • in The Biology Files
  • in inkfish
  • in Life of a Lab Rat
  • in The Greenhouse
  • in PLEKTIX
  • in Chinleana
  • in RRResearch
  • in The Culture of Chemistry
  • in Disease Prone
  • in The Phytophactor
  • in The Astronomist
  • in Epiphenom
  • in Sex, Genes & Evolution
  • in Skeptic Wonder
  • in The Large Picture Blog
  • in Memoirs of a Defective Brain
  • in C6-H12-O6
  • in The View from a Microbiologist
  • in Labs
  • in Doc Madhattan
  • in The Allotrope
  • in The Curious Wavefunction
  • in A is for Aspirin
  • in Variety of Life
  • in Pleiotropy
  • in Catalogue of Organisms
  • in Rule of 6ix
  • in Genomics, Evolution, and Pseudoscience
  • in History of Geology
  • in Moss Plants and More
  • in Protein Evolution and Other Musings
  • in Games with Words
  • in Angry by Choice

Is India's new antimalarial drug worth the hype?

I have an article published in Chemistry World today discussing the hype around this drug launch. I've already written about Ranbaxy's new antimalarial drug Synriam on this blog in the two previous posts, but there are a few new pieces of information in the recent article.

Here is a full set of references for the article:
  1. Ranbaxys' press release
  2. Ranbaxy's Synriam brochure
  3. Ranbaxy, Cipla unveil malaria combo drugs - DNA
  4. Daiichi to buy Ranbaxy stakes for $4.6 bn - The Financial Express
  5. Malaria deaths are down but progress remains fragile - The WHO
  6. Jonathan Vennerstrom et al. Nature 2004
  7. Jonathan Vennerstrom et al. J. Med. Chem. 2010

No comments:

Post a Comment

Markup Key:
- <b>bold</b> = bold
- <i>italic</i> = italic
- <a href="http://www.fieldofscience.com/">FoS</a> = FoS

Related Posts Plugin for WordPress, Blogger...